Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes

19 May 2021

Abstract excerpt

Alzheimer's disease (AD) affects tens of millions of people worldwide. Despite the advances in understanding the disease, there is an increased urgency for pharmacological approaches able of impacting its onset and progression. With a multifactorial nature, high incidence and prevalence in later years of life, there is growing evidence highlighting a relationship between metabolic dysfunction related to diabetes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amino Acid Enzymes and Metabolism
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34069618
DOI: 10.3390/biomedicines9050576

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and DiabetesPMID 34069618Read ↗

The Metabolic Basis for Nervous System Dysfunction in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s DiseaseSemantic proximity Read ↗

Taking aim at Alzheimer's disease through the mammalian target of rapamycinSemantic proximity Read ↗

Association Between Type 2 Diabetes Mellitus and Alzheimer's Disease: Common Molecular Mechanism and Therapeutic TargetsSemantic proximity Read ↗

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegenerationSemantic proximity Read ↗

Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes MellitusSemantic proximity Read ↗

mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in NeurodegenerationSemantic proximity Read ↗

Alzheimer’s Disease and Type 2 Diabetes Relationships. I. Cellular and Molecular Common Pathological MechanismsSemantic proximity Read ↗

mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesisSemantic proximity Read ↗

mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorderSemantic proximity Read ↗

Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and NeurodegenerationSemantic proximity Read ↗

Common Signaling Pathways Involved in Alzheimer’s Disease and Stroke: Two Faces of the Same CoinSemantic proximity Read ↗

Insulin and Autophagy in NeurodegenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.